Conclusions
cardiovascular disease, Diabetes
BLOOD, TYPE 2 DIABETES, CARDIOVASCULAR DISEASE, DIABETES
The BPROAD study will provide important evidence as to whether intensive blood pressure management has additional benefits on cardiovascular disease and all‐cause mortality among patients with type 2 diabetes.
Highlights

The Blood Pressure Control Target in Diabetes (BPROAD) study is a multicenter, randomized controlled trial conducted in mainland China to test the hypothesis of whether intensive blood pressure (BP) management (systolic BP <120 mm Hg) has additional benefits over standard BP management (systolic BP <140 mm Hg) over a follow‐up period of up to 5 years in patients with type 2 diabetes.Findings from the BPROAD study will guide the development of clinical guidelines for blood pressure management aimed at reducing cardiovascular disease burden.